[go: up one dir, main page]

AR132934A2 - Medio de cultivo celular suplementado con taurina y métodos de utilización - Google Patents

Medio de cultivo celular suplementado con taurina y métodos de utilización

Info

Publication number
AR132934A2
AR132934A2 ARP240101487A ARP240101487A AR132934A2 AR 132934 A2 AR132934 A2 AR 132934A2 AR P240101487 A ARP240101487 A AR P240101487A AR P240101487 A ARP240101487 A AR P240101487A AR 132934 A2 AR132934 A2 AR 132934A2
Authority
AR
Argentina
Prior art keywords
dupilumab
taurine
culture medium
cell culture
temperature
Prior art date
Application number
ARP240101487A
Other languages
English (en)
Inventor
Amy S Johnson
Meghan E Casey
Shadia Oshodi
Shawn Lawrence
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56738219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR132934(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of AR132934A2 publication Critical patent/AR132934A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C12N2500/33—Amino acids other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/46—Amines, e.g. putrescine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/74—Undefined extracts from fungi, e.g. yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La memoria descriptiva describe una composición que comprende un medio mejorado de cultivo de células eucarióticas, la cual se puede utilizar para la producción de una proteína de interés. Se puede agregar taurina al medio libre de suero o al medio químicamente definido para aumentar la producción de una proteína de interés. Se incluyen métodos para expresar recombinantemente niveles elevados de proteína utilizando las composiciones que comprenden el medio. Reivindicación 1: Un método para cultivar células eucarióticas recombinantes para la producción mejorada de dupilumab, caracterizado porque comprende las etapas de: (a) propagar las células eucarióticas recombinantes en un medio de cultivo celular definido durante una fase de crecimiento, donde dicho medio de cultivo celular está libre de glutamina; (b) suplementar el medio de cultivo celular definido con aproximadamente 0,1 mM a aproximadamente 10 mM de L-taurina y uno o más de los siguientes: 0 mM a 11,2 mM de alanina, 2,4 mM a 11,9 mM de arginina, 1,3 mM a 33,3 mM de asparagina, 1,5 mM a 93,9 mM de ácido aspártico, 1,1 mM a 19,9 mM de cisteína, 1,4 mM a 47,6 mM de ácido glutámico, 0 mM a 16,7 mM de glicina, 1 mM a 9,5 mM de histidina, 1,5 mM a 22,9 mM de isoleucina, 1,5 mM a 38,1 mM de leucina, 2,7 mM a 24,6 mM de lisina, 1,3 mM a 13,4 mM de metionina, 1,2 mM a 18,2 mM de fenilalanina, 1,7 mM a 26,1 mM de prolina, 1,9 mM a 57,1 mM de serina, 1,7 mM a 33,6 mM de treonina, 0,5 mM a 14,7 mM de triptofano, 0,9 mM a 22,2 mM de tirosina, y 1,7 mM a 34,1 mM de valina; y (c) expresar dupilumab durante la fase de producción, donde la adición de L-taurina incrementa el título de dupilumab en al menos 3% comparado con células que expresan dupilumab en un medio de cultivo celular que contiene menos de 0,1 mM de L-taurina. Reivindicación 13: Un método para cultivar células eucarióticas recombinantes para la producción mejorada de dupilumab, caracterizado porque comprende las etapas de: (a) propagar las células en un medio de cultivo celular definido durante una fase de crecimiento, y (b) suplementar el medio de cultivo celular definido con aproximadamente 0,1 mM a aproximadamente 10 mM de L-taurina, y expresar dupilumab durante la fase de producción, donde la adición de L-taurina incrementa el título de dupilumab en al menos 7% comparado con células que expresan dupilumab en un medio de cultivo celular que contiene menos de 0,1 mM de L-taurina, y donde dicha propagación de las células durante dicha fase de crecimiento se lleva a cabo a una temperatura de aproximadamente 35ºC a 38ºC, y dicha expresión de dupilumab durante dicha fase de producción se lleva a cabo a una temperatura de aproximadamente 29ºC a 37ºC, donde la temperatura de dicha fase de crecimiento es mayor que la temperatura de dicha fase de producción. Reivindicación 19: Un método para producir dupilumab caracterizado porque comprende las etapas de: (a) cultivar células que expresan dupilumab en un medio de cultivo celular que comprende de aproximadamente 0,1 mM a aproximadamente 10 mM de L-taurina, donde la adición de L-taurina incrementa el título de dupilumab en al menos un 3% a un 7% en comparación con las células que expresan dupilumab en un medio de cultivo celular que contiene menos de 0,1 mM de L-taurina; y (b) producir dupilumab en la célula, donde el dupilumab se secreta al medio, donde dichas células se cultivan a una temperatura de aproximadamente 35ºC a 38ºC durante una fase de crecimiento y aproximadamente 29ºC a 37ºC durante una fase de producción, donde la temperatura de la fase de crecimiento es mayor que la temperatura de la fase de producción. Reivindicación 23: Un método para producir dupilumab caracterizado porque comprende cultivar una línea celular recombinante en un medio de cultivo celular que comprende al menos aproximadamente 0,1 mM de L-taurina, donde la línea celular recombinante comprende un ácido nucleico integrado en forma estable que codifica dupilumab, y producir dupilumab a partir de las células, donde la adición de L-taurina al medio de cultivo celular incrementa el título del dupilumab en al menos 3% a 7% en comparación con cultivar la línea celular recombinante en un medio de cultivo celular que contiene menos de 0,1 mM de L-taurina; y donde dicha línea celular recombinante se cultiva a una temperatura de aproximadamente 35ºC a 38ºC durante una fase de crecimiento y aproximadamente 29ºC a 37ºC durante una fase de producción, donde la temperatura de la fase de crecimiento es mayor que la temperatura de la fase de producción.
ARP240101487A 2015-08-04 2024-06-11 Medio de cultivo celular suplementado con taurina y métodos de utilización AR132934A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562200689P 2015-08-04 2015-08-04

Publications (1)

Publication Number Publication Date
AR132934A2 true AR132934A2 (es) 2025-08-13

Family

ID=56738219

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP160102388A AR105602A1 (es) 2015-08-04 2016-08-04 Medio de cultivo celular suplementado con taurina y métodos de utilización
ARP240101487A AR132934A2 (es) 2015-08-04 2024-06-11 Medio de cultivo celular suplementado con taurina y métodos de utilización
ARP240101486A AR132933A2 (es) 2015-08-04 2024-06-11 Medio de cultivo celular suplementado con taurina y métodos de utilización

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP160102388A AR105602A1 (es) 2015-08-04 2016-08-04 Medio de cultivo celular suplementado con taurina y métodos de utilización

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP240101486A AR132933A2 (es) 2015-08-04 2024-06-11 Medio de cultivo celular suplementado con taurina y métodos de utilización

Country Status (16)

Country Link
US (8) US11312936B2 (es)
EP (3) EP4442808A3 (es)
JP (5) JP2018521664A (es)
KR (3) KR102709927B1 (es)
CN (2) CN114854668B (es)
AR (3) AR105602A1 (es)
AU (4) AU2016301305B2 (es)
BR (1) BR112018002214A2 (es)
CA (3) CA2989178C (es)
EA (1) EA201890137A1 (es)
HK (1) HK1248279A1 (es)
IL (5) IL298775B2 (es)
MX (2) MX390940B (es)
MY (3) MY203884A (es)
TW (5) TWI797060B (es)
WO (1) WO2017024062A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
JP7265494B2 (ja) * 2017-07-06 2023-04-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 糖タンパク質を作製するための細胞培養方法
CN108918892B (zh) * 2018-08-01 2021-04-27 百奥泰生物制药股份有限公司 一种测定抗vegf抗体活性的方法及其应用
JP7707062B2 (ja) * 2018-11-02 2025-07-14 ウーシー バイオロジクス アイルランド リミテッド 連続的採取を行い細胞流出を行わない強化灌流による細胞培養法
HU231514B1 (hu) * 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
EP4357448A3 (en) * 2019-01-17 2024-07-10 Boehringer Ingelheim Vetmedica GmbH Serum-free medium for avian vaccine production and uses thereof
CN109777793B (zh) * 2019-03-15 2020-12-08 常熟理工学院 一种gdsl脂肪酶、基因工程菌及其应用
US10961500B1 (en) 2019-04-23 2021-03-30 Regeneron Pharmaceuticals, Inc. Cell culture medium for eukaryotic cells
WO2020229584A1 (en) * 2019-05-16 2020-11-19 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
CN114901804A (zh) * 2019-11-04 2022-08-12 鲁比厄斯治疗法股份有限公司 使用牛磺酸或亚牛磺酸产生去核红系细胞的方法
CN110862972B (zh) * 2019-11-07 2020-10-30 衡阳师范学院 一种犬腺病毒ⅰ型无血清培养方法
EP3906249A1 (en) 2019-12-06 2021-11-10 Regeneron Pharmacetucals, Inc. Anti-vegf protein compositions and methods for producing the same
CN113005082B (zh) * 2019-12-20 2023-08-18 苏州依科赛生物科技股份有限公司 一种t细胞无血清培养基及其应用
CN113025590B (zh) * 2019-12-24 2022-08-09 华熙生物科技股份有限公司 一种提高环糊精葡萄糖基转移酶分泌表达的优化方法及其应用
BR112022020899A2 (pt) * 2020-04-15 2022-12-27 Genentech Inc Método para tratamento de um meio de cultura celular, meio de cultura celular, uso do meio e método para produzir uma proteína recombinante
KR20230008830A (ko) 2020-05-08 2023-01-16 리제너론 파마슈티칼스 인코포레이티드 Vegf 트랩 및 미니-트랩 및 안구 장애 및 암의 치료 방법
CN116761880A (zh) * 2021-01-20 2023-09-15 瑞泽恩制药公司 改进细胞培养物中的蛋白质滴度的方法
KR102296986B1 (ko) * 2021-01-21 2021-08-31 정덕수 우태아혈청 성분의 유해함을 극복하기 위한 화학적으로 정의된 줄기세포배양액 개발
CN113480652B (zh) * 2021-07-30 2023-04-07 成都景泽生物制药有限公司 一种重组cho细胞发酵培养生产重组egfr抗体活性分子的方法
KR20230080056A (ko) 2021-11-29 2023-06-07 (주)아모레퍼시픽 릴린 및/또는 vegf-c의 생산 및/또는 활성 촉진제 및 이를 이용한 피부 외용제
US20230331776A1 (en) 2022-03-02 2023-10-19 Regeneron Pharmaceuticals, Inc. Manufacturing process for high titer antibody
CN115029313B (zh) * 2022-08-12 2022-11-01 依科赛生物科技（太仓）有限公司 一种用于t细胞培养基的氨基酸组合物
CN118240744B (zh) * 2024-03-06 2024-11-26 上海迈邦生物科技有限公司 一种同时调节细胞表达产物聚体、电荷异质性和提高产量的方法
WO2025199245A1 (en) * 2024-03-19 2025-09-25 Immunis, Inc. Method of making and using secretome composition
CN118697740A (zh) * 2024-06-27 2024-09-27 华中科技大学同济医学院附属协和医院 次黄嘌呤在抗肿瘤免疫治疗中的应用

Family Cites Families (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072565A (en) 1974-11-04 1978-02-07 The Dow Chemical Company Production of viruses in tissue culture without use of serum
US3883511A (en) 1974-03-07 1975-05-13 Rit Rech Ind Therapeut New 6-aminopenicillanic acid derivative
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DE3271210D1 (en) 1981-12-24 1986-06-19 Asahi Chemical Ind Method for the cultivation of normal diploid cells and cultivation medium used therefor
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
FR2543158B1 (fr) 1983-03-24 1985-11-15 Inst Nat Sante Rech Med Milieu de culture de cellules animales sans serum, sans hormones et sans facteurs de croissance et procedes de culture primaire et d'obtention de lignees cellulaires utilisant ce milieu
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
JP2755395B2 (ja) 1987-09-23 1998-05-20 ブリストル―マイアーズ スクイブ コムパニー Ｈｉｖ感染細胞に殺作用する抗体異種結合体
DE3801236A1 (de) 1988-01-18 1989-07-27 Boehringer Mannheim Gmbh Pentosansulfat-medium
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5529920A (en) 1988-12-14 1996-06-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human liver epithelial cell line and culture media therefor
EP0449950A4 (en) 1988-12-14 1991-10-16 Us Health Cell culture medium for human liver epithelial cell line
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
WO1991000360A1 (en) 1989-06-29 1991-01-10 Medarex, Inc. Bispecific reagents for aids therapy
DE59010908D1 (de) 1989-09-12 2000-08-10 Hoffmann La Roche TNF-bindende Proteine
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
JP2897043B2 (ja) * 1989-12-21 1999-05-31 東ソー株式会社 完全合成培地
ATE139258T1 (de) 1990-01-12 1996-06-15 Cell Genesys Inc Erzeugung xenogener antikörper
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
JP3230091B2 (ja) 1990-06-25 2001-11-19 ウェルファイド株式会社 ヒト血清アルブミンの着色抑制方法
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1992009298A1 (en) 1990-11-23 1992-06-11 Peptide Technology Ltd. The delay, prevention and/or reversal of cell senescence
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
ATE181571T1 (de) 1991-09-23 1999-07-15 Medical Res Council Methoden zur herstellung humanisierter antikörper
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5658786A (en) 1992-03-04 1997-08-19 Synaptic Pharmaceutical Corporation DNA encoding rat taurine transporter and uses thereof
JPH07102147B2 (ja) 1992-03-16 1995-11-08 株式会社ミドリ十字 ヒト血清アルブミンの着色抑制方法
WO1994004690A1 (en) 1992-08-17 1994-03-03 Genentech, Inc. Bispecific immunoadhesins
PL174494B1 (pl) 1992-11-13 1998-08-31 Idec Pharma Corp Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B
US5426699A (en) 1993-10-25 1995-06-20 Antec Corporation Method and apparatus for digitizing a scrambled analog video signal
EP0666312A1 (en) 1994-02-08 1995-08-09 Wolfgang A. Renner Process for the improvement of mammalian cell growth
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6656466B1 (en) 1995-06-06 2003-12-02 Genetech, Inc. Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
HUP0202974A3 (en) 1995-07-17 2005-05-30 Fraunhofer Ges Forschung Metal-containing ribonucleotide polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
JP4306813B2 (ja) 1995-09-19 2009-08-05 アスビオファーマ株式会社 動物細胞の新規培養方法
US6043092A (en) 1996-03-18 2000-03-28 University Of Pittsburgh Cell culture media for mammalian cells
US6146847A (en) 1996-11-01 2000-11-14 Genespan Corporation Stabilized transient gene expression
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US20080318254A9 (en) 1997-03-10 2008-12-25 The Regents Of The University Of California PSCA antibodies and hybridomas producing them
US20020012991A1 (en) 1997-04-07 2002-01-31 Florence Chua Nee Ho Kit Fong Cell culture media for enhanced protein production
US20020173629A1 (en) 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU7984498A (en) 1997-06-25 1999-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Serum-free cell growth medium
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
WO1999035255A2 (en) * 1998-01-12 1999-07-15 Betagene, Inc. Compositions and methods for regulated secretion from neuroendocrine cell lines
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
CA2329945C (en) * 1998-06-10 2012-07-17 University Of South Florida Electrofusion chamber
DK1167537T3 (da) 1999-03-30 2008-11-10 Japan Tobacco Inc Fremgangsmåde til fremstilling af et monoklonalt antistof
WO2000057891A1 (en) 1999-03-30 2000-10-05 Trustees Of Boston University Compositions and methods for producing platelets and/or proplatelets from megakaryocytes
AT409379B (de) 1999-06-02 2002-07-25 Baxter Ag Medium zur protein- und serumfreien kultivierung von zellen
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
IL146890A0 (en) 1999-06-08 2002-08-14 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
CN1114619C (zh) 1999-06-25 2003-07-16 中国科学院上海细胞生物学研究所 小鼠杂交瘤株Hepama－1分泌的肝癌鼠源单克隆抗体的制备方法
JP2003512821A (ja) 1999-10-04 2003-04-08 メディカゴ インコーポレイテッド 外来性遺伝子の転写調節方法
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
RU2192884C2 (ru) 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
ATE325865T1 (de) 2001-01-16 2006-06-15 Regeneron Pharma Isolierung von sezernierte proteine exprimierenden zellen
EP1463522A4 (en) 2001-05-16 2005-04-13 Einstein Coll Med HUMAN ANTIPNEUMOKOKKEN ANTIBODIES OF NON-THUMBAN ANIMALS
US20030087372A1 (en) 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
EA014802B1 (ru) 2001-08-23 2011-02-28 Генмаб А/С АНТИТЕЛА К ИНТЕРЛЕЙКИНУ 15 (ВАРИАНТЫ), СПОСОБ ИХ ПОЛУЧЕНИЯ, ИММУНОКОНЪЮГАТ НА ИХ ОСНОВЕ, ГИБРИДОМА, ТРАНСФЕКТОМА, ТРАНСГЕННОЕ ЖИВОТНОЕ, ЭКСПРЕССИОННЫЙ ВЕКТОР (ВАРИАНТЫ) И НУКЛЕИНОВАЯ КИСЛОТА ДЛЯ ИХ ПОЛУЧЕНИЯ, СПОСОБ ЛЕЧЕНИЯ (ВАРИАНТЫ) И СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЙ, ОПОСРЕДОВАННЫХ ИЛ-15, СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОДУКЦИИ TNF-α И СПОСОБ ИНГИБИРОВАНИЯ ИНДУЦИРОВАННОЙ ИЛ-15 ПРОЛИФЕРАЦИИ КЛЕТОК
EP1321515A1 (en) 2001-12-21 2003-06-25 Ingenium Pharmaceuticals AG Method of culturing cells
CN1180080C (zh) 2002-01-18 2004-12-15 中国科学院上海细胞生物学研究所 一种改进的肝癌鼠源单克隆抗体的制备方法
CN1302337C (zh) 2002-03-08 2007-02-28 Asml荷兰有限公司 光刻投射设备、所用的反射掩模以及器件制作方法
US20030190710A1 (en) * 2002-03-28 2003-10-09 Devries Ruth L. Control of glycoforms in IgG
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
WO2003101189A1 (en) 2002-05-29 2003-12-11 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7371922B2 (en) 2002-07-31 2008-05-13 The Board Of Trustees Of The University Of Illinois Nuclear transfer with porcine embryonic stem cells
US6924124B1 (en) 2002-08-23 2005-08-02 Immunex Corporation Feeding strategies for cell culture
US20060258841A1 (en) 2003-01-17 2006-11-16 Josef Michl Pancreatic cancer associated antigen, antibody thereto, and diagnostic and treatment methods
WO2004069172A2 (en) 2003-01-30 2004-08-19 The Government of the United States of America as represented by the Department of Veterans Affairs Multilineage-inducible cells and uses thereof
SI1623019T1 (sl) 2003-05-15 2010-10-29 Wyeth Llc Omejeno glukozno dovajanje za živalsko celično kulturo
AU2004270103B2 (en) 2003-05-21 2012-02-23 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies against Bacillusanthracis protective antigen
US7303694B2 (en) 2003-07-17 2007-12-04 Wisconsin Alumni Research Foundation Liquid crystals with reduced toxicity and applications thereof
US7462487B2 (en) 2003-09-18 2008-12-09 Raven Biotechnologies, Inc. Cell culture media
WO2005121176A1 (en) 2004-06-08 2005-12-22 Chengdu Kanghong Biotechnologies Co. Ltd Angiogenesis-inhibiting chimeric protein and the use
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
EP1812557A4 (en) * 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
US8273553B2 (en) 2004-11-02 2012-09-25 Ares Trading S.A. Production of growth hormone in serum-free cell culture medium for mammalian cells
EP1848745B1 (en) 2005-02-18 2014-07-09 Medarex, L.L.C. Monoclonal antibodies against cd30 lacking in fucosyl residues
KR20080005563A (ko) 2005-04-21 2008-01-14 글렌 에이. 골드스타인 불임과 연관된 산화성 스트레스의 치료를 위한ｎ-아세틸시스테인 아미드(ｎａｃ 아미드)
KR20070122497A (ko) 2005-04-22 2007-12-31 제넨테크, 인크. Ｃｄ20 항체로 치매 또는 알츠하이머병을 치료하는 방법
DE102005046225B4 (de) * 2005-09-28 2012-01-05 Cellca Gmbh Verbessertes Zellkulturmedium
AR058140A1 (es) 2005-10-24 2008-01-23 Wyeth Corp Metodo de produccion proteica utilizando compuestos anti-senescencia
PT1974014T (pt) 2006-01-04 2017-05-26 Baxalta Inc Meios de cultura celulares livres de oligopeptídeos
EP1818392B1 (en) 2006-02-14 2010-08-25 Genetix Limited Cell culture medium
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
WO2007119774A1 (ja) 2006-04-13 2007-10-25 Chugai Seiyaku Kabushiki Kaisha タウリントランスポーター遺伝子
HRP20120175T1 (hr) 2006-06-02 2012-03-31 Regeneron Pharmaceuticals Antitijela s visokim afinitetom za humani il-6 receptor
CN101501185A (zh) 2006-06-09 2009-08-05 人类起源公司 胎盘巢(placental niche)及其培养干细胞的用途
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
US7605237B2 (en) * 2006-10-02 2009-10-20 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
RU2520810C2 (ru) 2006-11-08 2014-06-27 Вайет Рационально разработанные среды для культивирования клеток
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
DK2150617T3 (en) 2007-06-04 2015-01-12 Regeneron Pharma Regions with increased expression and stability
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
PL2178916T3 (pl) 2007-07-31 2015-08-31 Regeneron Pharma Ludzkie przeciwciała przeciwko ludzkiemu CD20 i sposób ich zastosowania
EP2186905B1 (en) 2007-08-07 2016-07-13 Chugai Seiyaku Kabushiki Kaisha Method of producing heterogeneous protein
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
CN100482786C (zh) 2007-12-28 2009-04-29 天津百若克医药生物技术有限责任公司 一种人胚肾293细胞扩增无蛋白培养基
KR101594046B1 (ko) 2008-01-09 2016-02-15 첼카 게엠베하 개선된 배양 배지 첨가제 및 이를 이용한 방법
CN102224239A (zh) 2008-09-26 2011-10-19 先灵公司 高效价抗体生产
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
KR101641526B1 (ko) 2009-06-02 2016-07-21 리제너론 파마슈티칼스 인코포레이티드 푸코실화-결핍 세포
CN101603026B (zh) * 2009-06-19 2011-01-19 华东理工大学 适于动物细胞产品生产的无动物来源低蛋白培养基
MY164121A (en) 2009-06-26 2017-11-30 Regeneron Pharma Readily isolated bispecific antibodies with native immunoglobulin format
WO2011008770A2 (en) 2009-07-14 2011-01-20 Biogen Idec Ma Inc. Methods for inhibiting yellow color and peroxide formation in a composition
KR101574056B1 (ko) 2009-07-31 2015-12-02 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
KR20180010324A (ko) 2009-08-11 2018-01-30 제넨테크, 인크. 글루타민-비함유 세포 배양 배지에서의 단백질의 생성
EP2516624B1 (en) 2009-12-23 2020-02-05 Merck Sharp & Dohme Corp. Cell line 3m
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
WO2012006594A1 (en) 2010-07-08 2012-01-12 Baxter International Inc. Method of producing recombinant adamts13 in cell culture
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
KR20130101034A (ko) 2010-08-31 2013-09-12 프리슬랜드 브랜즈 비브이 진핵 세포를 위한 배양 배지
AR083044A1 (es) 2010-09-27 2013-01-30 Regeneron Pharma Anticuerpos anti-cd48 y usos de los mismos
IL283424B2 (en) 2010-10-06 2023-09-01 Regeneron Pharma Stabilized formulations that include antibodies against the interleukin receptor (il-4r)
SG190129A1 (en) 2010-11-05 2013-06-28 Abbvie Inc Efficient and effective supplement screening for the development of chemically defined media in cell culture
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
CN102093978A (zh) 2010-12-17 2011-06-15 上海市农业科学院 猪早期胚胎发育前期培养液及后期培养液
JP6001456B2 (ja) 2010-12-28 2016-10-05 中外製薬株式会社 動物細胞の培養方法
US20120171161A1 (en) 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
EP2697361A1 (en) 2011-04-11 2014-02-19 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
WO2013063510A1 (en) * 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
SMT201800092T1 (it) 2011-11-14 2018-03-08 Regeneron Pharma Composizioni e metodi per aumentare la massa muscolare e la forza muscolare antagonizzando specificamente gdf8 e/o activina a
EA033387B1 (ru) 2012-01-23 2019-10-31 Regeneron Pharma СТАБИЛИЗИРОВАННЫЕ СОСТАВЫ, СОДЕРЖАЩИЕ АНТИТЕЛА ПРОТИВ Ang-2
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
JP6090735B2 (ja) 2012-03-02 2017-03-08 国立大学法人山口大学 消化器系がん幹細胞を培養するための無血清培地、及びそれを用いた消化器系がん幹細胞の増殖方法
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
JP5940147B2 (ja) 2012-04-25 2016-06-29 国立研究開発法人理化学研究所 心筋指向性細胞を含む細胞製剤
JO3820B1 (ar) 2012-05-03 2021-01-31 Regeneron Pharma أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها
WO2013184809A1 (en) 2012-06-05 2013-12-12 The Regents Of The University Of California Methods and compositions for the rapid production of retinal pigmented epithelial cells from pluripotent cells
BR112014031842B1 (pt) 2012-06-21 2020-09-15 Baxalta GmbH Método para remover um contaminante viral de uma preparação
TW201843172A (zh) 2012-06-25 2018-12-16 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
SG11201500480TA (en) 2012-08-02 2015-02-27 Sanofi Sa Article of manufacture comprising aflibercept or ziv-aflibercept
JP6309521B2 (ja) 2012-08-13 2018-04-11 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ｐＨ依存性結合特性を有する抗ＰＣＳＫ９抗体
AU2013305063A1 (en) 2012-08-20 2015-03-19 Schreder Method of and system for isolating LED luminaires from electrical surges
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN112522353A (zh) 2012-10-10 2021-03-19 中外制药株式会社 经修饰的宿主细胞的建立方法
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
US9173380B2 (en) 2013-02-18 2015-11-03 Garmin Switzerland Gmbh Animal indicator apparatus
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
TWI659968B (zh) 2013-03-14 2019-05-21 再生元醫藥公司 針對呼吸道融合病毒ｆ蛋白質的人類抗體及其使用方法
US20160237400A1 (en) 2013-03-15 2016-08-18 The Jackson Laboratory Isolation of non-embryonic stem cells and uses thereof
EA034834B1 (ru) 2013-03-15 2020-03-26 Ридженерон Фармасьютикалз, Инк. Антагонисты il-33 и их применение
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
KR20210037745A (ko) * 2013-03-15 2021-04-06 제넨테크, 인크. 항산화제를 함유하는 세포 배양 조성물 및 폴리펩티드 생산 방법
CA2908407C (en) 2013-05-29 2022-06-14 F. Hoffmann-La Roche Ag Quantitative control of sialylation
JP6108170B2 (ja) * 2013-07-30 2017-04-05 株式会社大阪ソーダ 細胞培養用培地
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
JP2017502922A (ja) * 2013-10-29 2017-01-26 アルブミディクス アクティーゼルスカブ 抗体組成物
WO2015105926A1 (en) 2014-01-08 2015-07-16 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
CN106029896B (zh) 2014-01-13 2020-10-27 美国安进公司 调控鸟氨酸代谢以操控重组蛋白的高甘露糖糖型含量
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
AU2015229591B2 (en) 2014-03-11 2020-10-22 Regeneron Pharmaceuticals, Inc. Anti-EGFRvlll antibodies and uses thereof
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SG10202003996YA (en) 2014-05-05 2020-06-29 Regeneron Pharma Humanized c5 and c3 animals
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
EP3152318A1 (en) 2014-06-03 2017-04-12 Lupin Limited Cell culture process for producing a protein
AU2015317899A1 (en) 2014-09-16 2017-04-06 Regeneron Pharmaceuticals, Inc. Anti-glucagon antibodies and uses thereof
TWI710573B (zh) 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
CN114807010B (zh) 2015-04-01 2024-11-29 勃林格殷格翰国际公司 细胞培养基
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
PT3353212T (pt) 2015-09-23 2022-01-05 Regeneron Pharma Anticorpos biespecíficos anti-cd3 otimizados e suas utilizações
KR101936049B1 (ko) 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
TW202140776A (zh) 2016-04-26 2021-11-01 美商美國泰福生技股份有限公司 細胞培養基
JP7265494B2 (ja) 2017-07-06 2023-04-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 糖タンパク質を作製するための細胞培養方法

Also Published As

Publication number Publication date
CN107922920B (zh) 2022-04-12
AR105602A1 (es) 2017-10-18
US11312936B2 (en) 2022-04-26
JP2018521664A (ja) 2018-08-09
KR102709927B1 (ko) 2024-09-26
CN114854668A (zh) 2022-08-05
TW202440904A (zh) 2024-10-16
US20250340832A1 (en) 2025-11-06
IL256525A (en) 2018-02-28
IL298775B1 (en) 2025-01-01
IL256525B1 (en) 2023-01-01
IL313855B1 (en) 2025-12-01
US10927342B2 (en) 2021-02-23
US12221619B2 (en) 2025-02-11
IL323287A (en) 2025-11-01
US12359165B2 (en) 2025-07-15
US20220235318A1 (en) 2022-07-28
US20240309315A1 (en) 2024-09-19
EP3331987A1 (en) 2018-06-13
EP4442808A3 (en) 2024-12-25
JP7781954B2 (ja) 2025-12-08
TWI870789B (zh) 2025-01-21
TW201718849A (zh) 2017-06-01
CA3236085A1 (en) 2017-02-09
JP2024098108A (ja) 2024-07-19
HK1248279A1 (zh) 2018-10-12
CA2989178A1 (en) 2017-02-09
CA3236082A1 (en) 2017-02-09
EP4442808A2 (en) 2024-10-09
AR132933A2 (es) 2025-08-13
AU2022291430B2 (en) 2024-11-14
IL313855A (en) 2024-08-01
EP4442807A2 (en) 2024-10-09
TW202330904A (zh) 2023-08-01
US20240309316A1 (en) 2024-09-19
AU2024204127A1 (en) 2024-07-04
KR20240144464A (ko) 2024-10-02
AU2022291430A1 (en) 2023-02-02
TWI899515B (zh) 2025-10-01
US20240018467A1 (en) 2024-01-18
MY192561A (en) 2022-08-29
MY208943A (en) 2025-06-12
IL256525B2 (en) 2023-05-01
JP7198868B2 (ja) 2023-01-04
IL298775A (en) 2023-02-01
EP4442807A3 (en) 2025-01-01
JP2024098107A (ja) 2024-07-19
WO2017024062A1 (en) 2017-02-09
US20250327023A1 (en) 2025-10-23
TWI797060B (zh) 2023-04-01
US20200157492A1 (en) 2020-05-21
MY203884A (en) 2024-07-23
IL313856A (en) 2024-08-01
US20180223249A1 (en) 2018-08-09
CA2989178C (en) 2025-10-07
MX390940B (es) 2025-03-21
KR20180032581A (ko) 2018-03-30
CN107922920A (zh) 2018-04-17
KR20240144463A (ko) 2024-10-02
JP2021112215A (ja) 2021-08-05
IL298775B2 (en) 2025-05-01
AU2016301305B2 (en) 2022-09-29
US12359166B2 (en) 2025-07-15
EA201890137A1 (ru) 2018-07-31
BR112018002214A2 (pt) 2018-09-04
JP7495451B2 (ja) 2024-06-04
HK1250740A1 (zh) 2019-01-11
TW202340452A (zh) 2023-10-16
MX2022003477A (es) 2022-04-25
CN114854668B (zh) 2025-06-03
TW202440903A (zh) 2024-10-16
AU2016301305A1 (en) 2018-01-25
MX2018001531A (es) 2018-04-24
AU2024204125A1 (en) 2024-07-04
IL313856B1 (en) 2025-10-01
JP2022162157A (ja) 2022-10-21

Similar Documents

Publication Publication Date Title
AR132934A2 (es) Medio de cultivo celular suplementado con taurina y métodos de utilización
AR124871A2 (es) Métodos de fabricación para el control del contenido de lisina c-terminal, galactosa y ácido siálico en proteínas recombinantes
UA129709C2 (uk) ПОЛІПЕПТИД З ПРОТЕАЗНОЮ АКТИВНІСТЮ IdeS
MX2020011334A (es) Cultivo celular metabolicamente optimizado.
EA201590488A1 (ru) Способы модификации клеток-хозяев
CL2016003096A1 (es) Métodos para cosechar cultivos de células de mamífero
MX355650B (es) Produccion de proteinas en medios de cultivo de celulas libres de glutamina.
EA201690529A1 (ru) Способы модификации клетки-хозяина
MX2015015606A (es) Composiciones detergentes.
EA201491470A1 (ru) Композиции фактора viii и способы получения и использования подобных
EA201492185A1 (ru) Способ получения рекомбинантной идуронат-2-сульфатазы
MX394537B (es) Enzimas y aplicaciones de las mismas.
EA201170715A1 (ru) Вектор, содержащий множественные гомологичные нуклеотидные последовательности
ES2627117T3 (es) Método basado en MGMT para obtener un rendimiento elevado de expresión de proteínas recombinantes
EA201491144A1 (ru) Способ флокуляции
EA201590550A1 (ru) Композиции и способы получения гликопротеинов
EA202091349A1 (ru) Способы культивирования клеток
MX2017008410A (es) Reduccion selectiva de residuos cisteina en anticuerpos il-17.
EA202190736A1 (ru) Способы и композиции для увеличения экспрессии белка и/или лечения расстройства, связанного с гаплонедостаточностью
PE20211303A1 (es) Polipeptidos del factor vii de accion corta
CO2019012871A2 (es) Métodos de cultivo celular para expresar proteínas con heterogeneidad reducida
AR097805A1 (es) Células de cambio de temperatura para la expresión de alto rendimiento de polipéptidos en levadura y otros transformados
CO2017011431A2 (es) Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina
CA2830600C (en) Compositions and methods for enhancing the pluripotency of stem cells
MX393714B (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.